Critical Illness Polyneuropathy and Myopathy

Background: Intensive care unit-acquired weakness (ICU-AW) poses a significant challenge in critically ill patients, impacting their clinical course and outcomes. First documented in the early 1980s, ICU-AW encompasses conditions such as Critical Illness Myopathy (CIM), Critical Illness Polyneuropathy (CIP), and diaphragmatic weakness. Identified risk factors for ICU-AW include high severity of illness, sepsis, multiple organ failure, prolonged immobilization, hyperglycemia, thyrotoxicosis, older age, and systemic inflammatory response syndrome (SIRS). ICU-AW is prevalent in approximately 25% of patients undergoing prolonged mechanical ventilation. Diagnosis: Diagnostic challenges arise due to limitations in clinical examinations within the ICU setting. Handgrip dynamometry and Medical Research Council (MRC) scores are useful in awake patients, but electrophysiological studies (Edx) are often required. CIP, characterized by axonal sensorimotor polyneuropathy, presents with reduced amplitude of compound motor or sensory action potentials. Differential diagnosis between CIP and CIM can be challenging. Distinguishing ICU-AW from other neuromuscular conditions, such as Guillain-Barré syndrome, requires careful consideration of clinical and neurophysiological features. Treatment: Management involves addressing underlying conditions and minimizing exposure to potentially exacerbating agents. Mobilization and physical rehabilitation play a central role, with early initiation showing potential protective effects. Pharmacological treatments lack sufficient evidence, and nutritional support remains an area of ongoing investigation. In conclusion, ICU-AW represents a complex syndrome with multifaceted challenges in diagnosis, management, and prognosis, necessitating ongoing research to enhance our understanding and develop effective interventions.